

Ghana

Support for Vaccine: Meningococcal type A This Decision Letter sets out the Programme Terms of a Programme.

1. Country:	Ghana						
2. Vaccine grant number:	16-GHA-08j-Y, 1619-GHA-28a-X, 20-GHA-28a-X						
3. Date of Decision Letter:	30 September 2019						
4. Date of the Partnership Framework Agreement:	11 July 2014						
5. Programme title:	New Vaccine Support (NVS), Meningococcal type A, Routine						
6. Vaccine type:	Meningococcal type A						
7. Requested product presentation and formulation of vaccine:	Meningococcal type A, 10 dose(s) per vial, LYOPHILISED						
8. Programme Duration:¹	2016-2020						
9. Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	2016-2019	2020	2021	2022	2023	2024	Total ²
Programme Budget (US\$)	1,945,912	333,000	-	-	-	-	2,278,912
10. Vaccine introduction grant							
	Approval						
	Year	Grant Number					Amount (US\$)
	2016	16-GHA-08j-Y					914,500
	Disbursement						
	Disbursement date						Amount (US\$)
	03 June, 2016						914,500
11. Product switch grant	Not applicable						
12. Indicative Annual Amounts:³	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	Type of supplies to be purchased with Gavi funds	2016-2019					2020
	Number of vaccine doses						590,800

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

Annual Amounts (US\$)	1,945,912	333,000														
13. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.															
14. Self-procurement:	Not applicable															
15. Co-financing obligations:	<p>According to the co-financing policy, the Country falls within the group: Preparatory transition phase</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th>2020</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>686,000</td> </tr> <tr> <td>Number of AD syringes</td> <td>567,100</td> </tr> <tr> <td>Number of re-constitution syringes</td> <td>75,500</td> </tr> <tr> <td>Number of safety boxes</td> <td>7,075</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>371,605</td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>416,000</td> </tr> </tbody> </table> <p>In order to mitigate risks of stocking out in 2020, co-financing obligation associated with this program should be fulfilled by June 2020.</p>		Type of supplies to be purchased with Country funds in each year	2020	Number of vaccine doses	686,000	Number of AD syringes	567,100	Number of re-constitution syringes	75,500	Number of safety boxes	7,075	Value of vaccine doses (US\$)	371,605	Total co-financing payments (US\$) (including freight)	416,000
Type of supplies to be purchased with Country funds in each year	2020															
Number of vaccine doses	686,000															
Number of AD syringes	567,100															
Number of re-constitution syringes	75,500															
Number of safety boxes	7,075															
Value of vaccine doses (US\$)	371,605															
Total co-financing payments (US\$) (including freight)	416,000															
16. Operational support for campaigns:	Not applicable															
17. Additional Reporting Requirements:	<table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. </td> <td> 31 March 2020 15 May 2020 </td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Gavi Secretariat</td> </tr> </tbody> </table>			Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2020 15 May 2020	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat								
	Due dates															
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2020 15 May 2020															
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat															

18. Financial clarifications:

Not applicable

19. Other conditions:

Not applicable

Signed by,

On behalf of Gavi



Thabani Maphosa,
Managing Director, Country Programmes
30 September 2019